Modelling the potential effect of cabamiquine-pyronaridine for chemoprevention against Plasmodium falciparum malaria
File(s) Revised paper draft AAC 2 clean.docx (108.86 KB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Preventive treatment (chemoprevention) is a key intervention for reducing the burden of Plasmodium falciparum malaria in children. The impact of the current widely-used drug combination, sulphadoxine–pyrimethamine-amodiaquine (SP-AQ), is challenged by emerging drug resistance and adherence to multi-day dosing. Cabamiquine is a novel antimalarial with activity against liver and blood stage malaria parasites, administered as a single dose and under development in combination with pyronaridine. We used mathematical modelling to translate early phase 1 clinical results into estimates of its potential impact as malaria chemoprevention. Pharmacokinetic–pharmacodynamic (PKPD) models of cabamiquine and pyronaridine were combined, assuming Bliss independence, to estimate time-varying protection against infection. PKPD results were incorporated into an established individual-based malaria transmission model to evaluate the impact of seasonal malaria chemoprevention (SMC) across settings with differing transmission and seasonality. Cabamiquine–pyronaridine was predicted to provide protection of >95% for approximately four weeks, slightly outperforming SP-AQ even in children who fully adhere to SP-AQ treatment. Six weeks after treatment, cabamiquine-pyronaridine protection dropped for the regimens containing <200mg cabamiquine, but the combination could still outperform SP-AQ at doses ≥200mg. When deployed as SMC, longer duration of protection may enable fewer, more widely spaced treatment cycles while maintaining impact, improving projected cost-effectiveness. Cabamiquine–pyronaridine shows strong potential as a next-generation single-dose chemoprevention regimen, supporting continued clinical development and evaluation.
Date Acceptance
2026-09-11
Citation
Antimicrobial Agents and Chemotherapy
ISSN
0066-4804
Publisher
American Society for Microbiology
Journal / Book Title
Antimicrobial Agents and Chemotherapy
Copyright Statement
Copyright This paper is embargoed until publication. Once published the author’s accepted manuscript will be made available under a CC-BY License in accordance with Imperial’s Research Publications Open Access policy (www.imperial.ac.uk/oa-policy).
License URL
Publication Status
Accepted
